Subscribe
1heals
1heals / iStockphoto.com
29 November 2017Big Pharma

Life sciences industry calls for Brexit transition period

The EU and UK must make progress in Brexit negotiations “as soon as possible”, according to the associations that represent the European and British life sciences industry.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
After Brexit: new directions for clinical trials
10 October 2017   If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.
Big Pharma
Big pharma companies react to ‘Brexit’
28 June 2016   Following the result of the UK’s referendum on membership of the EU, pharmaceutical companies have yet to find out how this will affect their businesses.


Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025

Editor's picks

Americas
Fed Circ ruling on Wuhan import ban shakes up economic prong analysis
11 February 2025

More on this story

Big Pharma
Big pharma companies react to ‘Brexit’
28 June 2016   Following the result of the UK’s referendum on membership of the EU, pharmaceutical companies have yet to find out how this will affect their businesses.
Big Pharma
After Brexit: new directions for clinical trials
10 October 2017   If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.

More on this story

Big Pharma
Big pharma companies react to ‘Brexit’
28 June 2016   Following the result of the UK’s referendum on membership of the EU, pharmaceutical companies have yet to find out how this will affect their businesses.
Big Pharma
After Brexit: new directions for clinical trials
10 October 2017   If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.

More features

Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules
Gilead deal staves off generic HIV drugs for another six years
Apple voids Omni MedSci wearable tech patent
Clifford Chance expands life sciences team with A&O Shearman hire
Vidal: ‘Erroneous’ jury instructions need to be fixed at Fed Circ
'A very good decision’: Patent industry welcomes UPC in-house reps update
Make a difference: Cast your vote in IP Diversity & Inclusion Awards 2025
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan